Themis Medicare Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹90 Cr +15.1% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
TM

Themis Medicare Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Themis Medicare Q1 FY27: Revenue ₹86.96 Cr, PAT ₹24.61 Cr

Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹87Cr
−10.9% YoY
+13.6% QoQ
Net profit
₹25Cr
Turned profitable YoY
+176.8% QoQ
Margin
−60.28%
−49.8 pp YoY
−65.2 pp QoQ

Based on Themis Medicare Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹118
Market cap₹1.1K Cr

The short version

Q1 FY27 Net Revenue: ₹86.96 crore. Q1 FY27 EBITDA: ₹(52.42) crore; Margin: (60.28)%.

From Themis Medicare Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q1 FY27 Net Revenue: ₹86.96 crore
  • Q1 FY26 Net Revenue: ₹97.58 crore
  • Year-on-Year (YoY) Revenue Change: -10.9%

2 more points from Themis Medicare Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Themis Medicare Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The investor presentation mentions the following capex, capacity expansion, and projects: - Vertical Integration with state-of-the-art manufacturing facilities: - Formulations plant in Haridwar - Synthetic APIs plants in Hyderabad and Vapi - Capacities: - Formulations: 520 mn tablets, 9 mn ointment tubes, 36 mn ampoules, 12 mn vials, 6 mn pre-filled syringes p.a. - Synthetic APIs: Hyderabad - 120 MT; Vapi - 191 MT p.a. - R&D Investments: - Consistent investment around Rs. 14 Cr annually over FY21-22 to FY25-26 (~8% of revenue) - Focus on development of 5–8 new products annually with documentation and 20–24 products in the pipeline - Expansion Plans: - New Target Markets:

2 more points from Themis Medicare Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Themis Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Themis Medicare Ltd said on order book & pipeline — free account, 30 seconds.

Themis Medicare Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Themis Medicare Ltd Q1 FY27 results — key figures

Themis Medicare Ltd Q1 FY27 reported results vs year-ago quarter, ₹ crore
₹ CrQ1 FY27
Revenue87
Operating profit (EBITDA)-52
Operating margin-60.3%
Profit before tax36
Net profit (PAT)25
EPS (₹)2.67

Source: Themis Medicare Ltd's results filing to NSE (consolidated), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹90 Cr, net profit ₹7 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjivani Paranteral (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Themis Medicare Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Themis Medicare Ltd Q1 FY27 results?

Q1 FY27 Net Revenue: ₹86.96 crore. Q1 FY27 EBITDA: ₹(52.42) crore; Margin: (60.28)%.

What is Themis Medicare Ltd share price analysis?

Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,142 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.